Special Issue

Advances in Animal Models and Precision Medicine for Cancer Research

Message from the Guest Editors

Treating individual patients based on specific factors, such as biomarkers, is what differentiates precision medicine from standard treatment regimens. The arrival of precision medicine has transformed translational cancer research, suggesting an approach that is patient-focused, with treatment choices directed by prognostic/predictive/monitoring biomarkers. The overall aim of translational research is to produce meaningful results that can quickly benefit cancer patients. Humans are complex organisms; if translational research is to be carried out, the models used should mimic that complexity. Animal models have been vital to cancer research, having been used in studies ranging from the investigation of the mechanisms of cancer development/progression, to studies on cancer drug screening and biomarker research. Major advancements have been made in recent decades on animal cancer models, which have become progressively more complex due to the use of new and improved technologies.

In this Special Issue, we invite authors to submit articles focusing on animal models and how their use can lead to advancements in precision medicine for cancer.

Guest Editors

Dr. James Meehan

The Royal (Dick) School of Veterinary Studies, Roslin Institute, The University of Edinburgh, Edinburgh, Midlothian, Scotland, UK

Dr. Mark E. Gray

The Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, Midlothian, Scotland, UK

Deadline for manuscript submissions

30 August 2025

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/202314

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

MDPI

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).